Table 3.
Covariate | R2 (Unstandardized β) Between Covariate and C2C:CPII | ΔR2 (Unstandardized β) Between Injury and Surgery and C2C:CPII after accounting for the covariate |
---|---|---|
Days Between Injury and Six-Month Follow-up | 0.025 (0.0002) | 0.194 (0.001) * |
Days Between ACLR and Six-Month Follow-up | 0.023 (0.0002) | 0.196 (0.001) * |
Body Mass Index | 0.001 (0.0002) | 0.213 (0.001) * |
Sex | 0.258 (−0.023) * | 0.207 (0.001) * |
Age | 0.029 (0.001) | 0.185 (0.001) * |
History of previous ACLR | 0.011 (−0.006) | 0.219 (0.001) * |
Concomitant Meniscal Injury | 0.056 (−0.011) | 0.201 (0.001) * |
Concomitant Chondral Injury | 0.051 (−0.011) | 0.165 (0.001) |
KOOS Symptoms at Initial Presentation | 0.001 (0.00003) | 0.223 (0.001) * |
KOOS Pain at Initial Presentation | 0.012 (−0.0001) | 0.202 (0.001) * |
KOOS Daily Living at Initial Presentation | 0.033 (−0.0002) | 0.180 (0.001) * |
KOOS Sports at Initial Presentation | 0.035 (0.0001) | 0.266 (0.001) * |
KOOS Quality of Life at Initial Presentation | 0.061 (−0.0003) | 0.158 (0.001) |
Tegner Activity Scale at Six-Month Follow-Up | 0.013 (−0.0006) | 0.190 (0.001) |
ACLR – Anterior Cruciate Ligament Reconstruction, KOOS – Knee Osteoarthritis and Outcome Score, C2C – Type-II Collagen Cleavage Product, CPII – C-Propeptide of Type-II Collagen Procollagen, ARGS – Alanin-Arginine-Glycine-Serine, IL-6 – Interleukin-6, MMP-3 – Matrix Metalloproteinase-3
Significant F Change at p ≤ 0.05